SLGL
(NASDAQ)
7.41
-0.3022  (-4.08%)
Volume (24h): 24,971.00 Day Range: 6.87 - 7.81
Market Cap: 166.72M 52W Range: 5.00 - 21.00
Mar-26-20 11:05AM Earnings Beat: Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsSimply Wall St.
Mar-25-20 03:08PM UPDATE -- Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor ConferenceGlobeNewswire
01:25PM Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor ConferenceGlobeNewswire
Mar-24-20 08:05PM Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate UpdateGlobeNewswire
08:00PM Solebury Trout Announces Virtual Conference Series with Presentations from Life Science CompaniesACCESSWIRE
Mar-19-20 09:45PM Sol-Gel Technologies to Report Full Year 2019 Financial Results and Corporate UpdateGlobeNewswire
Feb-19-20 02:25PM Sol-Gel to Present at the Cowen 40th Annual Health Care ConferenceGlobeNewswire
Feb-16-20 01:50PM 2 “Strong Buy” Healthcare Stocks with Over 100% Upside PotentialTipRanks
Feb-14-20 01:23PM The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices OfferingBenzinga
11:45AM Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary SharesGlobeNewswire
Feb-13-20 09:05PM Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 WeeksGlobeNewswire
Feb-05-20 12:05PM Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020GlobeNewswire
Jan-21-20 09:05PM Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 MeetingGlobeNewswire
Jan-08-20 12:00PM Sol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne VulgarisGlobeNewswire
Jan-02-20 12:30PM Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)GlobeNewswire
Dec-30-19 03:51PM Sol-Gel’s stock jumps 90% on positive acne-drug studiesMarketWatch
02:57PM Why Sol-Gel Shares Are Ripping HigherBenzinga
Dec-30-19 01:24PM Sol-Gel stock rockets on positive data from acne studyMarketWatch
12:05PM Sol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne VulgarisGlobeNewswire
Nov-29-19 04:17PM Hedge Funds Watching Sol-Gel Technologies Ltd. (SLGL) From AfarInsider Monkey
Nov-13-19 12:05PM Sol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate UpdateGlobeNewswire
Oct-16-19 11:05AM Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology ConferenceGlobeNewswire
Sep-04-19 12:38PM Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 40% Discount?Simply Wall St.
Aug-13-19 11:05AM Sol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate UpdateGlobeNewswire
Aug-08-19 12:10PM Sol-Gel Announces Pricing of Public Offering of Ordinary SharesGlobeNewswire
Aug-07-19 02:30PM Sol-Gel Technologies Ltd. (SLGL) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks
Jul-25-19 10:00AM Sol-Gel Technologies Hosting Analyst & Investor DayGlobeNewswire
Jul-11-19 12:15PM Investors Who Bought Sol-Gel Technologies (NASDAQ:SLGL) Shares A Year Ago Are Now Up 49%Simply Wall St.
Jul-08-19 01:12PM Sol-Gel Technologies Shares Positive Results For Skin Breakout CreamBenzinga
12:06PM UPDATE: Sol-Gel Technologies shares soar 9.5% on news of positive results in trials of rosacea treatmentMarketWatch
Jul-08-19 11:05AM Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular RosaceaGlobeNewswire
Jun-17-19 11:00AM Sol-Gel Technologies to Host Analyst & Investor Day on July 25, 2019GlobeNewswire
May-28-19 01:00PM Sol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with PerrigoGlobeNewswire
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)